Emerging drug targets for colon cancer: A preclinical assessment.

Madison M CrutcherTrevor R BaybuttJessica S KopenhaverAdam E SnookScott A Waldman

Published in: Expert opinion on therapeutic targets (2022)

Surgery and current systemic cytotoxic therapies are inadequate to appropriately treat the full spectrum of CRC, especially in those patients who present with metastatic or treatment-refractory disease. In addition to the identification of new, more generalizable targets, additional focus is being placed on novel administrations. Immuno-oncologic options and stem cell-targeting therapies for mCRC will become available to patients and may increase survival.

Keyphrases

stem cells
end stage renal disease
ejection fraction
newly diagnosed
small cell lung cancer
prognostic factors
emergency department
coronary artery bypass
patient reported outcomes
mesenchymal stem cells
cancer therapy
drug induced
bone marrow
acute coronary syndrome